Horizon Discovery Ltd. And Transgenomic, Inc. Announce Collaboration For Validation Control And Development Of Genetic Diagnostic Tests

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OMAHA, Neb. & CAMBRIDGE, England--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.

Help employers find you! Check out all the jobs and post your resume.

Back to news